Edwards Lifesciences Corp

  • 4 Opportunities for Growth

    By Cody Terrill - August 24, 2013 | Tickers: CAT, COH, EW, IBM

    In a year where the entire market is up 15%, it is easy to feel like you missed the boat if your assets were tied up elsewhere. Lucky for you there are still opportunities. Buying into strong established companies during favorable opportunities is a winning strategy. These four companies have been hit hard recently but the sun hasn’t set on them yet. They are poised for a nice comeback more »

  • Reasons to Buy These 3 Stocks

    By Brian Nichols - June 13, 2013 | Tickers: EW, FB, RFMD

    It has been a tough year for Edwards Lifesciences (NYSE: EW). The stock has declined 24% in 2013 alone due to disappointing sales.

    Canaccord’s Jason Mills came out with a note on Monday saying that he expects the company to prevail in its German patent infringement suit against Medtronic. The analyst also upgraded the stock with a “Buy” rating and a $85 price target.

    Edwards Lifesciences is a medical more »

  • Is This Fallen Angel Still a Good Growth Play?

    By Palwasha Saaim - June 11, 2013 | Tickers: EW, MDT, STJ

    Healthcare stocks resemble tech stocks, in that both are eye candy to growth investors, show volatility over business cycles and thus have less appeal to value investors. Conclusively, it is important for growth investors to understand that if they pick high-growth companies with a strong market presence, they are likely to reap greater rewards during down markets than up markets. The reason is obvious. During down markets, the stronger companies more »

  • Recent Aortic Valve Events that You Should Understand

    By Cory Renauer - June 3, 2013 | Tickers: BSX, EW, MDT

    Aortic stenosis is a type of heart disease involving a narrowing of the valve between the left ventricle of the heart and the aorta, or the aortic valve. According to the American Heart Association, about 0.4% of Americans have aortic stenosis, and the frequency of cases increases with age. About 2.8% of Americans aged 75 and older have moderate to severe aortic stenosis. Of those with severe symptoms more »

  • Edwards Lifesciences: A Strong Buy on Recent Dip

    By Palwasha Saaim - March 20, 2013 | Tickers: EW, MDT, STJ

    Back in October, when Edwards Lifesciences (NYSE: EW) missed earnings forecasts and the stock plummeted to its lowest in 10 years, I rated it a buy. If you had listened, you would have profited from the rally that followed. Now, after three months, history is repeating itself. 

    Edwards Lifesciences is a medical device manufacturer and holds a monopoly-like position in the U.S. for its Transcatheter Heart Valve (THV) called more »

  • Constant Growers For Your Portfolio

    By Steve Van - January 2, 2013 | Tickers: AAPL, CTXS, EW, ESRX

    While recently browsing in the business section of a used bookstore, I found a misplaced copy of “The Constant Gardener” by master spy novelist John le Carre.  I know very little about the plot of the novel but the title suggested an intriguing investment angle as it sat there, out of place, amongst the finance books.  An image of an old, rich man tending to his garden of growing stocks more »

  • Intuitive Surgical Fairly Valued, But Well Worth Buying on Pullback

    By Jordo Bivona - December 24, 2012 | Tickers: BSX, EW, ISRG

    Intuitive Surgical's (NASDAQ: ISRG) da Vinci Surgical System offers surgeons superior 3D HD visualization, enhanced dexterity, greater precision and ergonomic comfort for the optimal performance of MIS. The da Vinci System enables surgeons to perform even complex procedures, such as heart valve and cancer surgery through 1 to 2 centimeter incisions. This breakthrough is allowing hospitals everywhere to extend the benefits of MIS to a broader base of patients more »

  • New Test Can Boost Revenues Tenfold, One Insider Is Buying

    By Meena Krishnamsetty - December 20, 2012 | Tickers: EW, MXDHF, OPK, WAT

    Each year, there are around 200,000 distinct insider transactions reported to SEC via Form 4 filings. While the term "insider trading" sounds nefarious, there are just a handful of cases deemed illegal by federal prosecutors each year, though anomalous, above-average returns remain.

    On average, a host of empirical studies and our own research have found that individuals who mimic certain insider trades can beat the market by 7 percentage more »

  • Happy New Year, Edwards!

    By Palwasha Saaim - December 13, 2012 | Tickers: EW, MDT, STJ

    Twenty-twelve was the year of the Medical Devices Industry. The iShares Dow Jones Medical Devices ETF showed gains of over 14% year-to-date and has returned about 37% since inception. Companies like Edwards Lifesciences (NYSE: EW) and Intuitive Surgical (NASDAQ: ISRG) reached never-seen-before highs, returning 27.89% and 11.69%, respectively, during 2012. Medtronic (NYSE: MDT) also showed recovery from its Great Recession slump, returning 10.11% this year. Limping behind more »

  • A Billionaire Insider Bought This Healthcare Stock

    By Meena Krishnamsetty - November 2, 2012 | Tickers: BSX, EW, MDT, STJ, VAR

    On October 25, St. Jude Medical (NYSE: STJ) Board member John Brown purchased 25,000 shares of the company’s stock at an average price of $38.65 per share- an investment of nearly $1 million. Brown, a billionaire and former CEO of Stryker, joined the St. Jude Board in 2005. Insider purchases should be good signs for a stock: since an insider already has a strong economic connection to more »

  • Cashing in on Edwards Lifesciences' Lower Forecast

    By Palwasha Saaim - October 24, 2012 | Tickers: BSX, EW, ISRG, MDT

    For companies, there's nothing good about missing analyst forecasts. Missing guidance often marks the beginning of troubles at the company, and of course the stock price slumps. But for investors, forecast misses are sometimes good news. When Mr. Market jumps to sell his shares on such misses (mostly irrationally) and builds a downward pressure on stock prices, he makes way for average investors like you and me to find more »

  • Stocks Consolidating In Their Niches.

    By Paul Tatireta - October 1, 2012 | Tickers: ACN, ACT, BSX, EW, IRM, PPL

    Companies with winning or gaining streaks are emerging on the market.  They are companies which have really established themselves and enjoy investor confidence.  They are determined to commit their resources and vitality to maintain their hold, and the result is this: An investor’s package filled with new ideas, inventiveness, resourcefulness, and up-trending performance;  a goldmine which inspires the most pessimistic of investors to renewed confidence.  But as experienced investors more »

  • Why Are Insiders Selling These Two Stocks?

    By Meena Krishnamsetty - July 12, 2012 | Tickers: CRL, EW

    Many years of experience working directly with insiders has taught that there can be countless reasons an insider will sell shares of his company’s stock. When we keep track of insiders selling shares of their own stock, taking the time to look for those reasons instead of jumping to conclusions can help avoid bad decisions based on assumptions.

    Contrary to popular belief, officers and directors of public companies are more »

  • The Best Medical Device Stocks

    By Meena Krishnamsetty - June 19, 2012 | Tickers: BSX, EW, MDT, NUVA, STJ | Editor's Choice

    Recently, medical technology company, Medtronic (NYSE: MDT)announced a step toward the development of an artificial pancreas. It filed the final module of its Pre-Market Approval (PMA) application with the US Food and Drug Administration for the MiniMed 530G system featuring Threshold Suspend Automation. If approved, the MiniMed 530G will be the only integrated insulin pump and continuous glucose monitor in the US that automatically suspends insulin delivery if the more »

  • Five Ways to Play Heart Health

    By Streetwise Reports - April 24, 2012 | Tickers: ATRC, EW, HTWR, SPNC, VOLC

    For more interviews with sector experts and analysts, please sign-up for our newsletter at www.thelifesciencesreport.com.

    -------------

    George S. Mack, The Life Sciences Report

    You almost never hear an analyst say his sector is trading at a significant discount across all market caps. But when I interviewed Senior Analyst and Managing Director Jason Mills of Canaccord Genuity for The Life Sciences Report, that was his evaluation of the cardiovascular space more »

  • Price The Market Part 34

    By Glen Bradford - January 9, 2012 | Tickers: DIT, DVA, XRAY, EW, ESRX

    Hi, my name is Glen Bradford and after writing 34 of these introductions, I'm running out of good material. This is a story of my journey of me following through with my decision to price the S&P500. Welcome aboard.

    237. Davita (NYSE: DVA) reminds me a lot of my CAPS Netflix call. In a few months earlier this year, Davita got destroyed. Once the price dropped into the more »

  • J.P. Morgan Healthcare Conference Schedule: Day One

    By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

    The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

    I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)